Bio-Thera Launches Early-Stage Cancer Study Assessing Monoclonal Antibody
Chinese biotech Bio-Thera Solutions has begun dosing cancer patients in a phase 1 trial of its investigational monoclonal antibody, BAT6005, the company announced this week.
The open-label, dose-escalation trial is enrolling cancer patients with advanced solid tumors and evaluating BAT6005’s safety and tolerability as a single injected therapy. The study’s goal is to identify the maximum tolerated dose, pharmacokinetics and preliminary anti-tumor activity of the candidate, according to Bio-Thera.
According to ClinicalTrials.gov, the trial is being conducted at two hospitals in Shandong and Shanghai, China, and will enroll an estimated 36 participants.
BAT6005 targets TIGIT (T-cell immunoreceptor with Ig and ITIM domains), which has become a receptor of interest in cancer immunotherapy research. Bio-Thera intends to eventually evaluate the candidate alongside its novel PD-1 antibody, BAT1308, against a wide array of cancers.